Hanall Biopharma Is A Global Biopharmaceutical Company Based In Seoulsouth Koreafounded In 1973Originally A Pharmaceutical Producerit Transitioned To A Biopharmaceutical Focus In The Early 2000Sestablishing Advanced Research Facilities In Seoul And Suwonand Expanding Its International Presence With The Incorporation Of Hanall Pharmaceutical International In Marylandusa The Company Develops Both Generic And Specialty Drugs Across Various Therapeutic Areasincluding Neurologyophthalmologyimmunologyand Oncologynotable Products In Development Include Hl192 For Parkinson S Diseasehl036 For Dry Eye Diseasesand Hl161 For Autoimmune Diseaseswith Over 90 Drugs In Its Pipeline And More Than 170 Commercialized Productshanall Biopharma Emphasizes Significant Investment In Research And Developmentdedicating 15Of Its Annual Sales Earnings To This Areathe Company Collaborates With Global Pharmaceutical Firms And Academic Institutions To Enhance Its Product Offerings And Market Reach
